GE HEALTHCARE TECHNOLOGIES INC (GEHC)

Sector: Health Care

    Home/Companies/GEHC/Annual Meeting

2026 Annual Meeting Analysis

GE HEALTHCARE TECHNOLOGIES INC · Meeting: May 7, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

8

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of the 8 Director Nominees Named in this Proxy Statement for a One-Year Term

8 FOR
✓ FOR
Peter J. Arduini

As CEO and director since the January 2023 spin-off, Arduini's tenure overlaps with a 3-year price return of -13.8%, but the gap versus the peer group median (-13.3pp) does not reach the 20pp threshold required to trigger a vote against, and no other disqualifying flags apply.

✓ FOR
H. Lawrence Culp, Jr.sitting ceo outside board count check

Culp is Chair of GEHC and also serves as Chairman and CEO of GE Aerospace, meaning he holds one outside public board seat (GEHC) in addition to his own company's board, which is within the policy limit of two total for a sitting CEO; TSR underperformance does not reach the 20pp trigger threshold, so no disqualifying flag is present.

✓ FOR
Rodney F. Hochman

Hochman has served since the spin-off, has no overboarding issues (no current public company board seats beyond GEHC), attended at least 75% of meetings in 2025, and the 3-year TSR gap versus peers (-13.3pp) does not reach the 20pp threshold needed to trigger a vote against.

✓ FOR
Catherine Lesjak

Lesjak serves as Audit Committee Chair and is a designated financial expert with a strong CFO background; she also sits on the GE Aerospace board (one outside seat), attendance is adequate, and the peer TSR gap does not trigger a vote against.

✓ FOR
Kevin A. Lobonew director exempt from tsr triggertemporary overboarding waiver

Lobo joined the board in March 2026, well within the 24-month new-director exemption window, so the TSR trigger does not apply; he currently holds two outside board seats (GEHC and Parker-Hannifin) as a sitting CEO, which normally would be flagged, but the company has disclosed he will step down from Parker-Hannifin after its 2026 annual meeting, and the board has granted a temporary waiver — no permanent disqualifying condition exists.

✓ FOR
Anne T. Madden

Madden has served since the spin-off, holds no other public company board seats, is a designated audit committee financial expert, attended at least 75% of meetings, and the peer TSR gap does not reach the 20pp threshold.

✓ FOR
William J. Stromberg

Stromberg has served since the spin-off, holds no current public company board seats, chairs the Compensation Committee and serves as an audit committee financial expert, attended at least 75% of meetings, and the peer TSR gap does not reach the 20pp threshold.

✓ FOR
Phoebe L. Yang

Yang has served since the spin-off, holds one outside public board seat (Doximity), has relevant technology and healthcare expertise, attended at least 75% of meetings, and the peer TSR gap does not reach the 20pp threshold.

All eight director nominees receive a FOR vote. GEHC's 3-year price return of -13.8% is negative in absolute terms, which means the policy requires a gap of at least 20 percentage points below the peer group median before triggering a vote against any director. The actual gap is only -13.3pp, so the TSR trigger does not fire for any director. Kevin Lobo, who joined in March 2026, is independently exempt as a director within the 24-month new-director window. No overboarding, attendance, independence, or qualifications concerns warrant a vote against any nominee.

Say on Pay

✓ FOR

CEO

Peter J. Arduini

Total Comp

$18,562,794

Prior Support

94.4%%

The prior year say-on-pay vote received 94.4% support, well above the 70% threshold that would require a response. The pay structure is heavily performance-oriented: 92% of the CEO's total target compensation is variable and at-risk, split among performance stock awards (tied to 3-year organic revenue, cumulative adjusted earnings per share, and relative total shareholder return versus peers), stock options (which only have value if the stock price rises), and time-vested restricted stock. Base salary at roughly 7.5% of total target compensation is far below the 40% fixed-pay ceiling in the policy. The 2023 performance stock awards paid out at 95% of target — modestly below target — which is consistent with the company's stock performance and does not indicate a pay-for-performance disconnect warranting a vote against.

Auditor Ratification

✓ FOR

Auditor

Deloitte & Touche LLP

Tenure

3 yrs

Audit Fees

$17,003,000

Non-Audit Fees

$1,094,000

Deloitte has audited GEHC since 2022 (approximately 3 years), well below the 25-year tenure threshold that would raise independence concerns. Non-audit fees (audit-related fees of $1,074,000 plus tax and other fees of $20,000, totaling $1,094,000) represent about 6.4% of audit fees ($17,003,000), far below the 50% threshold that would trigger a vote against. Deloitte is a Big 4 firm fully appropriate for a $32 billion market cap company.

Overall Assessment

GEHC's 2026 annual meeting presents three standard proposals, all of which receive a FOR vote determination. The director slate is clean — no TSR trigger fires, no overboarding issues persist beyond a disclosed temporary waiver for a newly added director, and attendance and independence standards are met across the board. The auditor and executive compensation program both pass policy screens without material concern.

Filing date: March 19, 2026·Policy v1.2·high confidence

Compensation Peer Group

15 companies disclosed in 2026 proxy filing

ABTAbbott Laboratories
AAgilent Technologies, Inc.
BAXBaxter International Inc.
BDXBecton, Dickinson and Company
BSXBoston Scientific Corporation
DHRDanaher Corporation
EWEdwards Lifesciences Corporation
HOLXHologic, Inc.
ISRGIntuitive Surgical, Inc.
PHGKoninklijke Philips N.V.
MDTMedtronic plc
DGXQuest Diagnostics Incorporated
SMMNYSiemens Healthineers AG
SYKStryker Corporation
TMOThermo Fisher Scientific Inc.